AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
99 hedge funds and large institutions have $79.5M invested in AVEO Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 22 closing their positions.
239% more call options, than puts
Call options by funds: $12.3M | Put options by funds: $3.63M
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
2% less funds holding
Funds holding: 101 → 99 (-2)
52% less capital invested
Capital invested by funds: $166M → $79.5M (-$86.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.12M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$4.84M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$817K |
| 4 |
SC
Sculptor Capital
New York
|
+$798K |
| 5 |
D.E. Shaw & Co
New York
|
+$626K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
-$13.6M |
| 2 |
Millennium Management
New York
|
-$1.84M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$1.32M |
| 4 |
6CM
683 Capital Management
New York
|
-$1.26M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.16M |
AVEO Hedge Fund Activity: Q4 2018 in Review
99 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2018, worth a combined $79.5M — down 52% from $166M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AVEO and 21 opened new positions — a net loss of 1 holder — while 24 trimmed existing stakes and 30 added.
The largest buyer was Granahan Investment Management, adding an estimated $5.12M. The largest seller was Polar Capital, exiting entirely with an estimated $13.6M sold.
- 99 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2018, down from 101 in Q3 2018.
- Funds reported $79.5M of AVEO Pharmaceuticals, Inc. stock for Q4 2018, down 52% quarter-over-quarter.
- 21 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2018 and 22 closed out, a net change of -1 holder.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2018 was Granahan Investment Management, an estimated $5.12M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q4 2018 was Polar Capital, an estimated $13.6M sold.
Based on aggregated 13F filings for Q4 2018.